恒瑞医药：注射用磷罗拉匹坦帕洛诺司琼（HR20013）的药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the drug application of HR20013, which is intended for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic anticancer drugs in adult patients [1] Group 1 - The drug HR20013 is specifically designed to address nausea and vomiting associated with cancer treatment [1] - The acceptance of the drug application marks a significant step towards potential market entry for Heng Rui Medicine [1] - This development highlights the company's ongoing commitment to expanding its oncology product portfolio [1]